Last reviewed · How we verify
BBIBP-CorV vaccine
BBIBP-CorV is an inactivated whole-virus COVID-19 vaccine that stimulates immune responses against SARS-CoV-2.
BBIBP-CorV is an inactivated SARS-CoV-2 vaccine developed by Sinopharm. It has completed several clinical trials, including Phase 2 and 3 studies, and is being evaluated for booster strategies. The vaccine is not approved by the FDA but is widely used in other regions.
At a glance
| Generic name | BBIBP-CorV vaccine |
|---|---|
| Also known as | Sinopharm BBIBP-CorV |
| Sponsor | Cogna Technology Solutions LLC |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) SARS-CoV-2 virus particles that trigger both humoral and cellular immune responses. Upon vaccination, the immune system recognizes viral antigens and generates antibodies and T-cell responses to protect against COVID-19 infection. This approach uses a traditional vaccine platform of chemically inactivated pathogen.
Approved indications
- COVID-19 prevention in adults and children
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BBIBP-CorV vaccine CI brief — competitive landscape report
- BBIBP-CorV vaccine updates RSS · CI watch RSS
- Cogna Technology Solutions LLC portfolio CI